Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Current Taxes (2023 - 2025)

Telix Pharmaceuticals has reported Current Taxes over the past 3 years, most recently at $30.7 million for Q4 2025.

  • Quarterly Current Taxes fell 3.23% to $30.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.7 million through Dec 2025, down 3.23% year-over-year, with the annual reading at $30.7 million for FY2025, 2.18% up from the prior year.
  • Current Taxes was $30.7 million for Q4 2025 at Telix Pharmaceuticals, down from $31.8 million in the prior quarter.
  • Over five years, Current Taxes peaked at $31.8 million in Q4 2024 and troughed at $12.5 million in Q4 2023.
  • The 3-year median for Current Taxes is $30.7 million (2025), against an average of $25.0 million.
  • Year-over-year, Current Taxes surged 154.64% in 2024 and then dropped 3.23% in 2025.
  • A 3-year view of Current Taxes shows it stood at $12.5 million in 2023, then surged by 154.64% to $31.8 million in 2024, then decreased by 3.23% to $30.7 million in 2025.
  • Per Business Quant, the three most recent readings for TLX's Current Taxes are $30.7 million (Q4 2025), $31.8 million (Q4 2024), and $12.5 million (Q4 2023).